<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02647489</url>
  </required_header>
  <id_info>
    <org_study_id>PAMVAC1_15</org_study_id>
    <nct_id>NCT02647489</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted</brief_title>
  <acronym>PAMVAC</acronym>
  <official_title>Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Adjuvanted With Alhydrogel, GLA-SE or GLA-LSQ in Healthy Malaria-Naïve Adults and Healthy, Lifelong Malaria-Exposed, Nulligravid Adult Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université d'Abomey-Calavi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Malaria Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Recherche pour le Developpement</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Expres2ion Biotechnologies APS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite having developed robust acquired immunity against complications of malaria, women can&#xD;
      return to a susceptible state during their first pregnancies and contribute significantly to&#xD;
      the burden of severe malaria in highly endemic areas. Naturally acquired protection against&#xD;
      placental malaria correlates with the presence of high concentration of immunoglobulin G&#xD;
      molecules (IgGs) against VAR2CSA, a parasite protein of the var gene family that is essential&#xD;
      for the binding of infected erythrocytes to CSA in the placenta.&#xD;
&#xD;
      To induce high concentrations of specific IgGs, subjects will receive escalating doses of&#xD;
      PAMVAC vaccine antigen adjuvanted with Alhydrogel, Glucopyranosyl Lipid Adjuvant-Stable&#xD;
      Emulsion (GLA-SE) or Glucopyranosyl Lipid Adjuvant-Liposome-QS-21 Formulation (GLA-LSQ).&#xD;
      Three injections with the same dosage and adjuvant will be done, each 28 days apart (Day 0,&#xD;
      28 and 56). Control subjects will receive physiological saline instead of the vaccine and&#xD;
      dose escalation will be staggered to ensure safety during the trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1, staggered, two-center, dose-escalation trial. The trial will be conducted in two&#xD;
      stages. The first in Germany (first in man and dose escalation) and the second in a&#xD;
      malaria-endemic area in the target group (randomized, controlled, dose-finding).&#xD;
&#xD;
      First in man administration and dose escalation from 20 to 50 μg per injection of PAMVAC&#xD;
      adjuvanted with Alhydrogel, GLA-SE and GLA-LSQ will be done in healthy, malaria-naïve adults&#xD;
      in Germany (Stage 1).&#xD;
&#xD;
      Subsequently, PAMVAC will be administered to healthy, lifelong malaria-exposed nulligravid&#xD;
      women in Benin at doses of 50 and 100 μg, adjuvanted with Alhydrogel and GLA-SE (Stage 2).&#xD;
&#xD;
      The PAMVAC vaccine is a VAR2CSA protein-based vaccine, aiming to protect fetus and mother&#xD;
      against the adverse effects of placental malaria during pregnancy. As the interaction between&#xD;
      the parasite protein VAR2CSA and CSA in the human placenta is a key element in the&#xD;
      pathogenesis of placental malaria, a vaccine should elicit the type of immunoglobulins that&#xD;
      block the binding of VAR2CSA to CSA. A small sub-unit of the VAR2CSA protein (ID1-ID2a) has&#xD;
      been selected as the PAMVAC vaccine antigen. In animal models IgGs induced by immunization&#xD;
      with the recombinant PAMVAC antigen are able to inhibit homologous parasite-infected&#xD;
      erythrocyte adhesion to CSA in vitro.&#xD;
&#xD;
      The three adjuvants are Alhydrogel, an aluminum hydroxide gel widely used as adjuvant in this&#xD;
      trial; GLA-SE and GLA-LSQ, synthetic TLR-4 agonists with a strong immune stimulatory effect&#xD;
      formulated either in a stable oil-in-water emulsion (SE) or together with QS-21 (Saponin&#xD;
      derived from the Quillaja saponaria tree) as liposome (LSQ).&#xD;
&#xD;
      In Benin, one group will receive a placebo control (physiological saline). Allocation to&#xD;
      placebo, PAMVAC+Alhydrogel or PAMVAC+GLA-SE, will be randomized and the trial team as well as&#xD;
      the participants will be kept blinded (double-blinded) to their allocation.&#xD;
&#xD;
      All participants (Stage 1+2) will receive three intramuscular injections in four-week&#xD;
      intervals.&#xD;
&#xD;
      Each dose-escalation is conditional on a positive safety assessment by an independent Safety&#xD;
      Monitoring Board (SMB) and sponsor approval. One individual of each PAMVAC-adjuvant&#xD;
      combination will serve as sentinel. The sentinel will be injected one day before the rest of&#xD;
      the group.&#xD;
&#xD;
      There will be a minimum of 4 weeks stagger between the first immunization of Groups 1A-3A and&#xD;
      Groups 4A-6A.&#xD;
&#xD;
      Group 1A (n = 3) - 20 µg PAMVAC+Alhydrogel Group 2A (n = 3) - 20 µg PAMVAC+GLA-SE Group 3A (n&#xD;
      = 3) - 20 µg PAMVAC+GLA-LSQ Group 4A (n = 9) - 50 µg PAMVAC+Alhydrogel Group 5A (n = 9) - 50&#xD;
      µg PAMVAC+GLA-SE Group 6A (n = 9) - 50 µg PAMVAC+GLA-LSQ&#xD;
&#xD;
      Following safety assessment by the SMB after the first dose in Groups 4A-6A and approval by&#xD;
      the sponsor, Stage 2 (in Benin) will be initiated. Here, the target population of PAMVAC&#xD;
      (healthy nulligravid women in a malaria-endemic area) will be vaccinated. Upon SMB review and&#xD;
      approval by the sponsor Groups 1B-2B and half the subjects from the control Group 5B will&#xD;
      receive vaccinations. One participant allocated to group 1B, 2B and 5B will receive the first&#xD;
      immunization at least one day before the rest of the group.&#xD;
&#xD;
      Group 1B (n=9) - 50 µg PAMVAC+Alhydrogel Group 2B (n=9) - 50 µg PAMVAC+GLA-SE Group 3B (n=3)&#xD;
      - 100 µg PAMVAC+Alhydrogel Group 4B (n=3) - 100 µg PAMVAC+GLA-SE Group 5B (n=6) - Placebo&#xD;
      (physiological saline solution)&#xD;
&#xD;
      There will be a 4 weeks stagger between Groups 1B-2B and Group 3B-4B and the remaining&#xD;
      subjects of the control Group 5B to allow for safety evaluation by the SMB. Here, the same&#xD;
      system of sentinel vaccination as for the lower dose will be used; one participant allocated&#xD;
      to group 3B, 4B and 5B will receive the first immunization at least one day before the rest&#xD;
      of the group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">November 10, 2017</completion_date>
  <primary_completion_date type="Actual">November 10, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and grade of adverse events (Grade 1-3 and serious adverse events) possibly, likely and definitely related to vaccination</measure>
    <time_frame>From the first administration of the interventions through study completion, an average of 1 and a half years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of anti-PAMVAC IgG concentration</measure>
    <time_frame>Before first administration, 1, 4, 5, 8, 9, 12, 24 and 36 weeks after first administration</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Malaria, Antepartum</condition>
  <arm_group>
    <arm_group_label>1A - 20 µg PAMVAC + Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study participant will get 20 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2A - 20 µg PAMVAC + GLA-SE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study participant will get 20 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3A - 20 µg PAMVAC + GLA-LSQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study participant will get 20 µg of PAMVAC adjuvanted with GLA-LSQ administrated three times with each time 28 days interval (day 0-28-56)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4A - 50 µg PAMVAC + Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study participant will get 50 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5A - 50 µg PAMVAC + GLA-SE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study participant will get 50 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6A - 50 µg PAMVAC + GLA-LSQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study participant will get 50 µg of PAMVAC adjuvanted with GLA-LSQ administrated three times with each time 28 days interval (day 0-28-56)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1B - 50 µg PAMVAC + Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study participant will get 50 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2B - 50 µg PAMVAC + GLA-SE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study participant will get 50 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3B - 100 µg PAMVAC + Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study participant will get 100 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4B - 100 µg PAMVAC + GLA-SE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study participant will get 100 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5B - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The study participant will get Placebo (physiological saline solution) administrated three times with each time 28 days interval (day 0-28-56)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PAMVAC</intervention_name>
    <arm_group_label>1A - 20 µg PAMVAC + Alhydrogel</arm_group_label>
    <arm_group_label>1B - 50 µg PAMVAC + Alhydrogel</arm_group_label>
    <arm_group_label>2A - 20 µg PAMVAC + GLA-SE</arm_group_label>
    <arm_group_label>2B - 50 µg PAMVAC + GLA-SE</arm_group_label>
    <arm_group_label>3A - 20 µg PAMVAC + GLA-LSQ</arm_group_label>
    <arm_group_label>3B - 100 µg PAMVAC + Alhydrogel</arm_group_label>
    <arm_group_label>4A - 50 µg PAMVAC + Alhydrogel</arm_group_label>
    <arm_group_label>4B - 100 µg PAMVAC + GLA-SE</arm_group_label>
    <arm_group_label>5A - 50 µg PAMVAC + GLA-SE</arm_group_label>
    <arm_group_label>6A - 50 µg PAMVAC + GLA-LSQ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Alhydrogel</intervention_name>
    <arm_group_label>1A - 20 µg PAMVAC + Alhydrogel</arm_group_label>
    <arm_group_label>1B - 50 µg PAMVAC + Alhydrogel</arm_group_label>
    <arm_group_label>3B - 100 µg PAMVAC + Alhydrogel</arm_group_label>
    <arm_group_label>4A - 50 µg PAMVAC + Alhydrogel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GLA-SE</intervention_name>
    <arm_group_label>2A - 20 µg PAMVAC + GLA-SE</arm_group_label>
    <arm_group_label>2B - 50 µg PAMVAC + GLA-SE</arm_group_label>
    <arm_group_label>4B - 100 µg PAMVAC + GLA-SE</arm_group_label>
    <arm_group_label>5A - 50 µg PAMVAC + GLA-SE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GLA-LSQ</intervention_name>
    <arm_group_label>3A - 20 µg PAMVAC + GLA-LSQ</arm_group_label>
    <arm_group_label>6A - 50 µg PAMVAC + GLA-LSQ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>5B - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female volunteers aged 18-45 years.&#xD;
&#xD;
          -  Able and willing (in the investigator's opinion) to comply with all trial&#xD;
             requirements.&#xD;
&#xD;
          -  General good health based on history and clinical examination&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Women only: Must agree to practice continuous effective contraception for the duration&#xD;
             of the trial (a method which results in a low failure rate; i.e. less than 1% per&#xD;
             year). Women will be counseled about effective contraception methods and, if required,&#xD;
             can be provided with adequate contraceptives by the investigator team.&#xD;
&#xD;
          -  Available to participate in follow up for the duration of trial (36 weeks following&#xD;
             first injection)&#xD;
&#xD;
          -  Reachable by phone during the whole trial period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy, lactation or intention to become pregnant during the trial&#xD;
&#xD;
          -  Previous participation in a malaria vaccine trial&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient state, asplenia,&#xD;
             recurrent, severe infections and chronic (more than 14 days) immunosuppressant&#xD;
             medication within the past 6 months (inhaled and topical steroids are allowed)&#xD;
&#xD;
          -  Presence of autoimmune diseases requiring systemic treatment (e.g. rheumatic diseases)&#xD;
&#xD;
          -  Use of immunoglobulins or blood products within 3 months prior to enrolment&#xD;
&#xD;
          -  Receipt of an investigational product in the 30 days preceding enrolment, or planned&#xD;
             receipt during the trial period&#xD;
&#xD;
          -  History of malaria or travel in malaria-endemic areas within the past 6 months&#xD;
&#xD;
          -  Intention to travel to malaria endemic countries during the trial period&#xD;
&#xD;
          -  History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in&#xD;
             situ)&#xD;
&#xD;
          -  History of serious psychiatric condition that may affect participation in the trial&#xD;
&#xD;
          -  Any other serious chronic illness requiring hospital specialist supervision&#xD;
&#xD;
          -  Suspected or known current alcohol abuse as defined by an alcohol intake of greater&#xD;
             than 60 g (men) or 40 g (women) per day or a carbohydrate deficient transferrin (CDT)&#xD;
             level ≥2.5%&#xD;
&#xD;
          -  Suspected or known injecting drug abuse in the 5 years preceding enrolment&#xD;
&#xD;
          -  Positive for hepatitis B surface antigen (HBs-antigen)&#xD;
&#xD;
          -  Seropositive for hepatitis C virus (antibodies to HCV)&#xD;
&#xD;
          -  Volunteers unable to be closely followed for social, geographic or psychological&#xD;
             reasons&#xD;
&#xD;
          -  Known hypersensitivity to any of the vaccine components (adjuvant or peptide)&#xD;
&#xD;
          -  Any clinically significant abnormal finding on biochemistry or hematology blood tests,&#xD;
             urine analysis or clinical examination&#xD;
&#xD;
          -  History of seizure, except for sporadic febrile convulsions in childhood&#xD;
&#xD;
          -  Any other significant disease, disorder or finding which, in the opinion of the&#xD;
             investigator, may significantly increase the risk to the volunteer because of&#xD;
             participation in the trial; affect the ability of the volunteer to participate in the&#xD;
             trial or impair interpretation of the trial data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin G Mordmüller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tübingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Saadou Issifou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université d'Abomey-Calavi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Recherche Clinique du Benin (IRCB)</name>
      <address>
        <city>Abomey-Calavi</city>
        <country>Benin</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Benin</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>June 22, 2018</last_update_submitted>
  <last_update_submitted_qc>June 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

